Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly MOD-4023 vs Daily Genotropin in Pediatric GHD
NCT02968004Phase 3Completed
- Sponsor
- OPKO Health
- Start
- Dec 2016
- Primary completion
- Aug 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by OPKO Health. Primary endpoint: Annual Height Velocity at 52 weeks. Started Dec 2016; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02968004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968004.